Avaliação da progressão da fibrose hepática de pacientes co-infectados pelo HIV/HCV em serviços de atendimento a pacientes com HIV/AIDS / Evaluation of the progression of liver fibrosis of coinfected patients for the HIV/HCV in attendance services of patients with HIV/AIDS

AUTOR(ES)

Roberto Maximiliano Carrasco Navarro

DATA DE PUBLICAÇÃO

2008

RESUMO

BACKGROUND: Although theres growing evidence that the co-infection with HCV worsens the evolution of the HIV-related hepatotoxicity, the influence of the different factors associated to this remains poorly understood.This study intended to evaluate the epidemiological, laboratorial and HAART associated to the evolution of the fibrose progression rate (FPR) in co-infected patients followed in reference centers for the treatment of HIV/HCV in the city of São Paulo, Brazil. METHODS: 938 medical charts of co-infected patientes were reviewed for this study.and 102 fullfilled the inclusion and exclusion criteria to participate. A cross-sectional study evaluating socio-epidemiological aspects, laboratorial assesment and liver biopsy was performed and correlated with the fibrosis rate and the fibrosis progression rate (FPR). RESULTS: The population was characterized by male (83,3%), middle-age (42,9 years), white (53,9%) individuals, with a main risk factor of adquisition of both the infections trough illicit drugs-use (72,5%), mainly intravenous and alcohol consumption (75,5%), with predominance of HCV genotype 1 (56,9%) with a medium time of use of antiretrovirals of 7,9 years (SD=3,6 y). Histologic evaluation showed no relation between higher fibrosis degree in the liver biopsy related to the exposure of the antiretrovirals or even in the fibrosis progression rate (FPR). Illicit drugs abuse, including inaled and intravenous cocaine , were related to higher liver fibrosis rates and FPR. CONCLUSION: Our results emphasize the necessity of encourage the withdraw of ilicit drugs consumption in the HIV/HCV co-infected population in use of any antiretroviral regimen. Our study does no find any relation between the use of IP or NNRTI-based regimens and the poor prognosis of the liver fibrosis in this population.

ASSUNTO(S)

hepatic cirrhosis infection infecção biopsy highly active antiretroviral therapy hiv terapia anti-retroviral de alta atividade biópsia hepacivirus hiv hepacivirus cirrose hepática

Documentos Relacionados

• Análise de sobrevida de pacientes coinfectados HIV/HCV de um centro de referência em DST/AIDS no município de São Paulo
• Co-infecção HIV/HCV em pacientes de Botucatu e região
• Barriers to treatment of hepatitis C in HIV/HCV coinfected adults in Brazil
• Uso do score APRI na avaliação de doença hepática, após início de terapia antirretroviral, em pacientes portadores do HIV co-infectados com HCV versus monoinfectados por HIV
• Co-infecção por HIV/HCV em hospital universitário de Recife, Brasil